Document:

SUBSCRIPTION
AGREEMENT

 

Boston
Therapeutics, Inc.

1750
Elm Street, Suite 103

Manchester,
NH 03104

Tel.
(603) 935-9799

 

THIS
SUBSCRIPTION AGREEMENT made this _____day of ______________, 2012 by and between Boston Therapeutics, Inc., a Delaware corporation
(hereinafter “Company”), and the undersigned Subscriber (hereinafter “Subscriber”), who, for and in consideration
of the mutual promises and covenants set forth herein, do hereto agree as follows:

 

1.
Subscription. The Subscriber hereby subscribes for ____________ Shares (hereinafter “Shares”) of the Company’s
Common Stock, at a price of $0.50 per Share, and herewith tenders to the Company by certified bank funds for the subscription
in the amount of US$________________, which the Subscriber tenders herewith as payment for the Shares. For every two (2) shares
of Common Stock purchased, Subscriber shall receive, at no additional cost, a warrant to purchase one (1) share of Common Stock
in the form attached hereto as Exhibit A (the “Warrant”). The Warrant shall have a 5 year term and shall be
exercisable at any time after issuance at a price of $1.00 per share.

 

This
offering will terminate 180 days from the effective date of the Prospectus (as such term is defined below), although we may close
the offering on any date prior if the offering is fully subscribed. As there is no minimum amount of proceeds to be raised, the
funds will be deposited in the Company’s operating account and used set forth in the Use of Proceeds section of this prospectus.
If the Company does not sell all 20,000,000 Shares within 180 days from the date of the Prospectus, the offering for the balance
of the Shares will terminate and we will sell no further shares pursuant to the offering.

 

This
Subscription Agreement (hereinafter “Subscription”) is an offer by the Subscriber to subscribe for the securities
offered by the Company, and, subject to the terms hereof, shall become a contract for the sale of said securities upon acceptance
thereof by the Company.

 

2.
Acknowledgement. The undersigned acknowledges that, prior to signing this Subscription Agreement and making this offer
to purchase, he or she has received the Prospectus describing the offering of the Shares and Warrants by the Company as filed
with the United States Securities and Exchange Commission (the “Prospectus”), and that he or she understands the risks
of and other considerations relevant to, a purchase of the Shares and Warrants, including those described under the caption “Risk
Factors” in the Prospectus. The undersigned understands that the resale of the Shares must be effected in reliance on exemptions
from qualification in certain states. The undersigned represents that the undersigned is a resident of the state set forth in
the “Subscriber Information” section of the signature page below. The undersigned further acknowledges that, if the
undersigned is a natural person, the undersigned is at least 21 years of age.

 

3.
Acceptance of Subscription and Delivery of Shares and Warrants. This Subscription Agreement is made subject to the Company’s
discretionary right to accept or reject the Subscription herein. If the Company for any reason rejects this Subscription, the
Subscription will be refunded in full, without interest, and this Subscription Agreement shall be null, void and of no effect.
Acceptance of this Subscription by the Company will be evidenced by the execution hereof by an officer of the Company. Delivery
of the Shares and Warrants subscribed for herein will be made within three (3) days following the acceptance of this Subscription
by the Company.

 

    	 

    	 

    

 

The
undersigned hereby executes this Subscription Agreement as of the ____ day of __________, 2012, at ________________________, _______________________

 

                                      (city)                                           (state
or country)

 

	Investor
    Signature (if individual)	 	 
	 	 	 
	Print
    Name:	 	 

 

If
more than one name on the stock certificate, sign below:

 

	Second
    Investor Signature	 	 
	 	 	 
	Print
    Name:	 	 
	 	 	 
	Address,
    if different from First Investor	 	 
	 	 	 
	 	 	 

 

If
more than one name on the stock certificate, check status below:

 

	_____	Tenants
    in Common
	 	 
	_____	Joint
    Tenants with Right of Survivorship
	 	 
	_____	Other
    (describe): ______________________________________

 

Investor                         (if
entity)

 

	Print
    Entity Name:	 	 
	 	 	 
	Print
    Signatory Name:	 	 
	 	 	 
	By
    (signature):	 	 
	 	 	 
	Title:	 	 

 

Please
complete the Subscriber information on the following page.

 

    	2

    	 

    

 

Subscriber
Information:

 

	Name:	 	 
	Address:	 	 
	 	 	 

 

State
or Country: _______________________________Postal Code:________

 

Taxpayer
ID Number (if U.S. subscriber):____________________

 

	Driver’s
    License / Passport	 	 
	 	 	 
	Identification
    Number	 	 
	 	 	 
	email	 	_____________________________@______________________

 

 

    	3

    	 

    

 

EXHIBIT
A

WARRANTGENERAL
RELEASE and CHANGE of STATUS AGREEMENT

 

This
General Release and Change of Status Agreement (the “Agreement”) is made and entered into by and between Ache Stokelman
(“Executive”) and Oxygen Therapy, Inc. (“Company”) this 10th day of March, 2017 (the “Separation
Date”).

 

WHEREAS,
the Executive has advised the Company that he intends to withdraw as an officer and director of the Company, effective March
10, 2017; and

 

WHEREAS,
the Executive has confirmed his interest in continuing to provide services to the Company in a consulting capacity, and the Company
is interested in engaging Executive in that capacity;

 

WHEREAS,
in connection with his departure as an executive and a director of the company, Executive and Company have agreed that (a)
Executive should surrender some portion of the capital stock issued to him as a founder of the Company, (b) commencing on the
Separation Date, Executive will provide certain services to the Company in his capacity as a consultant and, for such services,
will receive warrants to purchase Company common stock, and (c) the Company will release the Executive from and waive any claims
it may have against Executive as set forth herein; and (d) the Executive will release the Company from and waive any claims he
may have against Company as set forth herein;

 

NOW,
THEREFORE, in consideration of the mutual promises contained herein and other consideration the sufficiency of which is hereby
acknowledged, the parties agree as follows:

 

1.      Separation
Date. As of the close of business on the Separation Date Executive’s employment as Chief Executive Officer of Company
will end effective and Executive will resign as a director of the Company.

 

2.      Redemption
of Shares. Executive has agreed to the Company’s redemption of 3,000,000 of the 5,000,000 share of common stock currently
held by Executive in consideration of $500.00, the receipt of which hereby is acknowledged; and Executive hereby agrees and confirms
that he will submit the certificate evidencing his shares to the Company’s transfer agent no later than March 20, 2017 with
the instruction that the transfer agent issue a new certificate to Executive for 2,000,000 shares within 10 business days.

 

3.      Company
Release of Executive. In consideration for the Executive’s promises described in this Agreement, the Company Released
Parties and their respective assigns, heirs, executors, and administrators, fully release the Executive from any and all liability,
claims, demands, actions, causes of action, suits, grievances, debts, sums of money, agreements, promises, damages, back and front
pay, costs, expenses, attorneys’ fees, and remedies of any type, regarding any act or failure to act that occurred up to
and including the Separation Date. The Company Release Parties and their respective assigns, heirs, executors and administrators
acknowledge that they may subsequently learn of facts or circumstances bearing on the rights or Claims released herein. Nonetheless,
the Company Released Parties and their respective assigns desire to achieve a release of all known and unknown Claims and rights
relating thereto. This Release is intended to unconditionally settle all Claims. For purposes of this Agreement, “Company
Released Parties,” as used in this Agreement, shall mean the Company and all of its affiliated companies and corporations
(if any), as well as the past and present officers, directors, agents, employees, officials, employee benefit plans (and their
sponsors, fiduciaries and administrators), insurers, and attorneys of Company and all of its affiliated companies and corporation.

 

    	1

    	 

    

 

4.      Executive
Release of Company. Executive, on behalf of himself and his agents, representatives, attorneys, assigns, heirs, executors,
and administrators, fully releases each of the Company Released Parties from any and all liability, claims, demands, actions,
causes of action, suits, grievances, debts, sums of money, agreements, promises, damages, back and front pay, costs, expenses,
attorneys’ fees, and remedies of any type, regarding any act or failure to act that occurred up to and including the Separation
Date, including but not limited to any claims under (1) the Age Discrimination in Employment Act, 29 U.S.C. §621 et seq.,
Title VII of the Civil Rights Act of 1964, 42 U.S.C. § 2000e et seq., the Americans With Disabilities Act of 1990, 42 U.S.C.
§ 12101 et seq., the Family and Medical Leave Act, 29 U.S.C. § 2601 et seq., the Worker Adjustment and Retraining Notification
Act (“WARN”), 29 U.S.C. § 2101 et seq., the Massachusetts Fair Employment Practices Act, M.G.L. c.151B, §
1 et seq. (or any equivalent in the State of New York), the Massachusetts Civil Rights Act, M.G.L. c.12, §§ 11H and
11I, the Massachusetts Equal Rights Act, M.G.L. c.93, § 102 and M.G.L. c.214, § 1C, the Massachusetts Labor and Industries
Act, M.G.L. c.149, § 1 et seq., and the Massachusetts Privacy Act, M.G.L. c.214, § 1B(or any equivalents in the State
of New York) , the Fair Credit Reporting Act, 15 U.S.C. § 1681 et seq. and the Employee Retirement Income Security Act of
1974 (“ERISA”), 29 U.S.C. § 1001 et seq., all as amended (“Claims”). Executive acknowledges that
he may subsequently learn of facts or circumstances bearing on the rights and Claims released herein. Nonetheless, Executive desires
to achieve a complete release of all known and unknown Claims and rights relating thereto. This Release is intended to unconditionally
settle all Claims. Notwithstanding the foregoing, (a) nothing in this Release prevents Executive from cooperating or participating
in any proceeding before the EEOC or a state Fair Employment Practices Agency (except that Executive acknowledges that he may
not recover any monetary benefits in connection with any such claim, charge or proceeding), (b) this Release does not extend to
any claims that: (i) arise out of or relate to Executive’s status as a stockholder of Company; and (ii) Executive is not
releasing his rights, if any, to any claims Executive may now or hereafter have for indemnification under the Executive’s
charter documents and/or By-laws, including the benefit of any so-called E&O or D&O policies of insurance

 

5.      Non-admission.
This Agreement does not constitute an admission by any of the Company Released Parties, and Company specifically denies that any
action or omission that any of the Company Released Parties has taken or has failed to take with respect to Executive was known
at the time of such act or omission by any of such Company Released Parties to be wrongful, unlawful, in violation of any local,
state, or federal act, statute, or constitution, or susceptible of inflicting any damage or injury on Executive.

 

6.      Agreement
Inadmissible as Evidence. This Agreement, its execution, and implementation may not be used as evidence, and shall not be
admissible, in a subsequent proceeding of any kind, except one which either party may bring alleging a breach of this Agreement.

 

7.      Entire
Agreement. This Agreement contains the entire agreement and understanding between Company and Executive concerning the matters
described herein, and supersedes all prior agreements, discussions, negotiations, understandings, and proposals of the parties.
The terms of this Agreement cannot be changed except in a subsequent document signed by the parties to this Agreement.

 

    	2

    	 

    

 

8.      Severability.
The provisions of this Agreement shall be severable and the invalidity of any provision shall not affect the validity of the other
provisions; provided, however, that if Executive brings a lawsuit, claim, charge, or complaint against any of the Company Released
Parties, and a court of competent jurisdiction finds that a release or waiver of claims or rights by Executive in paragraph 4
is illegal, void or unenforceable, Executive shall execute promptly a release, waiver and/or covenant that is legal and enforceable.

 

9.      Applicable
Law and Venue. This Agreement shall be construed and enforced in accordance with, and all questions concerning the construction,
validity, interpretation and performance of this Agreement shall be governed by, the laws of the Commonwealth of Massachusetts,
without giving effect to that state’s principles regarding conflict of laws. The parties agree that the Courts of Suffolk
County, Massachusetts shall have jurisdiction and venue over any dispute arising under this Agreement.

 

10.    Costs
and Attorneys’ Fees. If either party to this Agreement brings an action to enforce her or its rights under any provision
of this Agreement, the non-prevailing party in such action shall be liable to the prevailing party for the costs and reasonable
attorneys’ fees incurred by the prevailing party in connection with the action.

 

11.    Revocation
Period. Executive understands that he has the right to revoke this Agreement during a period of seven (7) days after he signs
it. In order to revoke this Agreement, Executive must sign and send a written notice by email of his decision to revoke this Agreement,
addressed to David Platt at David.Platt@otipharma.com. Executive understands that this Release shall not become effective and
in force until eight days after he signs it.

 

12.    Knowing
and Voluntary Waiver. Executive acknowledges that: (a) he has carefully read this Agreement and fully understands its meaning;
(b) he had the opportunity to take twenty-one (21) days to review this Agreement before signing it; (c) he was advised in writing
by Executive to consult with an attorney before deciding whether to sign this Agreement; (d) he is entering into this Agreement
knowingly and voluntarily; and (e) the only consideration he is receiving for signing this Agreement is described herein, and
no other promises or representations of any kind have been made by any person or entity to cause her to sign this Agreement.

 

Executed
as of this 10th day of March, 2017 in Boston, Massachusetts.

 

	/s/
    Ache Stokelman	 
	Ache
    Stokelman	 

 

Oxygen
Therapy, Inc.

 

	By:	/s/
    David Platt	 
	 	Chairman	 

 

    	3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}]]